دورية أكاديمية
أعرض في EDS

Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay.

التفاصيل البيبلوغرافية
العنوان: Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay.
المؤلفون: Hashimoto T; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Nakamura Y; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Oki E; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Kobayashi S; Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan., Yuda J; Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan., Shibuki T; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan., Bando H; Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Yoshino T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. tyoshino@east.ncc.go.jp.
المصدر: International journal of clinical oncology [Int J Clin Oncol] 2024 May; Vol. 29 (5), pp. 495-511. Date of Electronic Publication: 2024 Mar 29.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 9616295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1437-7772 (Electronic) Linking ISSN: 13419625 NLM ISO Abbreviation: Int J Clin Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 1998- : Tokyo : Springer-Verlag Tokyo
Original Publication: Tokyo : Published for the Japan Society of Clinical Oncology by Churchill Livingstone, c1996-
مواضيع طبية MeSH: Circulating Tumor DNA*/blood , Circulating Tumor DNA*/genetics , Neoplasm, Residual*/diagnosis , Neoplasm, Residual*/genetics , Whole Genome Sequencing*/methods , Biomarkers, Tumor*/blood , Biomarkers, Tumor*/genetics, Humans ; Japan ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/blood ; Colorectal Neoplasms/diagnosis ; Prognosis ; Precision Medicine/methods ; Neoplasms/genetics ; Neoplasms/blood ; Neoplasms/diagnosis
مستخلص: Circulating tumor DNA (ctDNA) is the fraction of cell-free DNA in patient blood that originates from a tumor. Advances in DNA sequencing technologies and our understanding of the molecular biology of tumors have increased interest in exploiting ctDNA to facilitate detection of molecular residual disease (MRD). Analysis of ctDNA as a promising MRD biomarker of solid malignancies has a central role in precision medicine initiatives exemplified by our CIRCULATE-Japan project involving patients with resectable colorectal cancer. Notably, the project underscores the prognostic significance of the ctDNA status at 4 weeks post-surgery and its correlation to adjuvant therapy efficacy at interim analysis. This substantiates the hypothesis that MRD is a critical prognostic indicator of relapse in patients with colorectal cancer. Despite remarkable advancements, challenges endure, primarily attributable to the exceedingly low ctDNA concentration in peripheral blood, particularly in scenarios involving low tumor shedding and the intrinsic error rates of current sequencing technologies. These complications necessitate more sensitive and sophisticated assays to verify the clinical utility of MRD across all solid tumors. Whole genome sequencing (WGS)-based tumor-informed MRD assays have recently demonstrated the ability to detect ctDNA in the parts-per-million range. This review delineates the current landscape of MRD assays, highlighting WGS-based approaches as the forefront technique in ctDNA analysis. Additionally, it introduces our upcoming endeavor, WGS-based pan-cancer MRD detection via ctDNA, in our forthcoming project, SCRUM-Japan MONSTAR-SCREEN-3.
(© 2024. The Author(s).)
References: Oncol Rep. 2023 May;49(5):. (PMID: 37052271)
Sci Adv. 2020 Dec 11;6(50):. (PMID: 33310847)
Front Oncol. 2020 Sep 15;10:561598. (PMID: 33042842)
Cancer Sci. 2021 Jul;112(7):2915-2920. (PMID: 33931919)
Int J Clin Oncol. 2021 Aug;26(8):1420-1430. (PMID: 34185174)
Blood. 2022 Sep 22;140(12):1345-1377. (PMID: 35797463)
BMC Cancer. 2020 Jun 30;20(1):612. (PMID: 32605647)
Diagnostics (Basel). 2022 Sep 03;12(9):. (PMID: 36140548)
Front Neurol. 2020 Oct 19;11:544680. (PMID: 33192972)
Haematologica. 2022 Dec 01;107(12):2810-2822. (PMID: 36453518)
Cancer Discov. 2017 Dec;7(12):1394-1403. (PMID: 28899864)
Nature. 2023 Apr;616(7957):553-562. (PMID: 37055640)
N Engl J Med. 2014 Dec 25;371(26):2477-87. (PMID: 25426838)
Cancers (Basel). 2021 Nov 14;13(22):. (PMID: 34830853)
Int J Cancer. 2021 Feb 1;148(3):528-545. (PMID: 32683679)
Ann Oncol. 2023 Oct;34(10):899-906. (PMID: 37597579)
Clin Cancer Res. 2021 Oct 15;27(20):5586-5594. (PMID: 33926918)
Blood. 2021 Dec 30;138(26):2753-2767. (PMID: 34724563)
Mol Oncol. 2022 Jan;16(2):549-561. (PMID: 34543520)
Gastric Cancer. 2022 Sep;25(5):906-915. (PMID: 35763187)
Gastroenterology. 2020 Feb;158(3):494-505.e6. (PMID: 31711920)
N Engl J Med. 2017 Jun 1;376(22):2109-2121. (PMID: 28445112)
Sci Transl Med. 2015 Aug 26;7(302):302ra133. (PMID: 26311728)
Nat Med. 2021 Nov;27(11):1899-1903. (PMID: 34764486)
Nat Commun. 2016 Aug 22;7:12484. (PMID: 27546487)
J Hematol Oncol. 2021 May 17;14(1):80. (PMID: 34001194)
JAMA Oncol. 2019 Aug 01;5(8):1124-1131. (PMID: 31070691)
Cancer Sci. 2022 May;113(5):1830-1842. (PMID: 35293110)
Int J Clin Oncol. 2017 Jun;22(3):421-430. (PMID: 28238187)
Science. 2018 Feb 23;359(6378):926-930. (PMID: 29348365)
Nat Commun. 2020 Jan 27;11(1):525. (PMID: 31988276)
Lancet Oncol. 2022 Oct;23(10):1274-1286. (PMID: 36108662)
Clin Cancer Res. 2019 Oct 15;25(20):6026-6034. (PMID: 31088829)
Proc Jpn Acad Ser B Phys Biol Sci. 2023 Oct 11;99(8):241-253. (PMID: 37558430)
Lancet. 2021 Oct 9;398(10308):1344-1357. (PMID: 34555333)
Sci Transl Med. 2016 Jul 6;8(346):346ra92. (PMID: 27384348)
Int J Clin Oncol. 2021 Nov;26(11):2142-2150. (PMID: 34259983)
Sci Transl Med. 2019 Aug 7;11(504):. (PMID: 31391323)
JAMA Oncol. 2019 Dec 1;5(12):1710-1717. (PMID: 31621801)
Int J Clin Oncol. 2021 Sep;26(9):1628-1639. (PMID: 34117553)
PLoS Med. 2021 May 3;18(5):e1003620. (PMID: 33939694)
Nature. 2014 Feb 20;506(7488):300-1. (PMID: 24522525)
Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):961-8. (PMID: 20080596)
Mol Oncol. 2023 May;17(5):825-838. (PMID: 36732646)
Nat Med. 2020 Jul;26(7):1114-1124. (PMID: 32483360)
Front Oncol. 2020 Jul 30;10:1220. (PMID: 32850360)
Ann Oncol. 2019 Nov 1;30(11):1804-1812. (PMID: 31562764)
Sci Transl Med. 2015 Apr 15;7(283):283ra53. (PMID: 25877891)
N Engl J Med. 2022 Jun 16;386(24):2261-2272. (PMID: 35657320)
J Clin Oncol. 2019 Jun 20;37(18):1547-1557. (PMID: 31059311)
JAMA Oncol. 2020 Dec 01;6(12):1890-1899. (PMID: 33030517)
JCO Precis Oncol. 2022 Apr;6:e2100535. (PMID: 35544728)
Ann Oncol. 2022 May;33(5):500-510. (PMID: 35306155)
Nature. 2021 Jul;595(7867):432-437. (PMID: 34135506)
Clin Cancer Res. 2018 Sep 15;24(18):4437-4443. (PMID: 29567812)
Front Oncol. 2022 Mar 04;12:834992. (PMID: 35311090)
Int J Cancer. 2016 Jun 15;138(12):2974-83. (PMID: 26815009)
Nat Med. 2023 Jan;29(1):127-134. (PMID: 36646802)
Radiother Oncol. 2020 Oct;151:182-189. (PMID: 32687856)
Ann Oncol. 2019 Sep 1;30(9):1472-1478. (PMID: 31250894)
Cancer Cell. 2023 Oct 9;41(10):1749-1762.e6. (PMID: 37683638)
Br J Cancer. 2022 May;126(8):1186-1195. (PMID: 35132238)
J Thorac Oncol. 2022 Mar;17(3):423-433. (PMID: 34740861)
J Clin Oncol. 2022 Aug 1;40(22):2408-2419. (PMID: 35658506)
JAMA Oncol. 2019 Oct 1;5(10):1473-1478. (PMID: 31369045)
Sci Transl Med. 2014 Feb 19;6(224):224ra24. (PMID: 24553385)
Clin Cancer Res. 2023 Aug 1;29(15):2748-2752. (PMID: 36892497)
Blood. 2022 Feb 10;139(6):835-844. (PMID: 34289038)
Cancer Cell. 2023 Oct 9;41(10):1763-1773.e4. (PMID: 37816331)
Clin Cancer Res. 2019 Jul 15;25(14):4255-4263. (PMID: 30992300)
EBioMedicine. 2023 May;91:104553. (PMID: 37027928)
Cancer. 2019 Mar 1;125(5):750-760. (PMID: 30561775)
Ann Surg. 2016 Feb;263(2):345-52. (PMID: 26501709)
Nat Biotechnol. 2021 Dec;39(12):1537-1547. (PMID: 34294911)
Haematologica. 2022 Dec 01;107(12):2794-2809. (PMID: 36453517)
Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. (PMID: 28428191)
Clin Chem. 2024 Feb 7;70(2):434-443. (PMID: 38069911)
Nature. 2017 Apr 26;545(7655):446-451. (PMID: 28445469)
Cancer Cell. 2014 Jun 16;25(6):713-4. (PMID: 24937455)
Mol Diagn Ther. 2021 Nov;25(6):757-774. (PMID: 34725800)
Transl Lung Cancer Res. 2022 Feb;11(2):263-276. (PMID: 35280315)
Ann Surg Oncol. 2022 Mar;29(3):1596-1605. (PMID: 34724126)
J Clin Oncol. 2016 Nov 1;34(31):3758-3765. (PMID: 27573660)
Clin Cancer Res. 2019 Aug 15;25(16):4973-4984. (PMID: 31142500)
Ann Oncol. 2019 May 1;30(5):804-814. (PMID: 30838379)
Nat Rev Cancer. 2017 Apr;17(4):223-238. (PMID: 28233803)
Clin Cancer Res. 2022 Aug 2;28(15):3308-3317. (PMID: 34844976)
BMC Clin Pathol. 2018 Nov 26;18:12. (PMID: 30498396)
Front Genet. 2023 Aug 10;14:1172108. (PMID: 37636270)
Nat Biomed Eng. 2022 Mar;6(3):257-266. (PMID: 35301450)
Clin Cancer Res. 2021 May 1;27(9):2515-2522. (PMID: 33602686)
Nat Rev Clin Oncol. 2018 Sep;15(9):577-586. (PMID: 29968853)
Clin Lung Cancer. 2024 Jan;25(1):e1-e4. (PMID: 37880076)
Blood Adv. 2020 Apr 28;4(8):1670-1677. (PMID: 32324887)
Cancer Discov. 2022 Jul 6;12(7):1690-1701. (PMID: 35543554)
N Engl J Med. 2014 Dec 25;371(26):2488-98. (PMID: 25426837)
Ann Oncol. 2021 Feb;32(2):229-239. (PMID: 33232761)
Int J Clin Oncol. 2020 Aug;25(8):1523-1532. (PMID: 32394048)
Nature. 2018 Nov;563(7732):579-583. (PMID: 30429608)
Cancer Discov. 2021 Dec 1;11(12):2968-2986. (PMID: 34785539)
Cell Death Dis. 2020 May 11;11(5):346. (PMID: 32393783)
Cancer Discov. 2014 Sep;4(9):1088-101. (PMID: 24920063)
Nat Commun. 2015 Jul 07;6:7686. (PMID: 26154128)
JCO Precis Oncol. 2022 Dec;6:e2200420. (PMID: 36480779)
Blood Adv. 2022 Jun 14;6(11):3294-3303. (PMID: 35320339)
Cancers (Basel). 2023 Mar 25;15(7):. (PMID: 37046628)
Clin Cancer Res. 2020 Jun 1;26(11):2556-2564. (PMID: 32170028)
J Clin Oncol. 2022 Sep 1;40(25):2924-2933. (PMID: 35576508)
iScience. 2023 Oct 19;26(12):108271. (PMID: 38047080)
Blood. 2015 Jul 2;126(1):9-16. (PMID: 25931582)
Blood. 2018 Mar 22;131(12):1275-1291. (PMID: 29330221)
فهرسة مساهمة: Keywords: CIRCULATE-Japan; Circulating tumor DNA; MONSTAR-SCREEN; Molecular residual disease; SCRUM-Japan; Whole genome sequencing
المشرفين على المادة: 0 (Circulating Tumor DNA)
0 (Biomarkers, Tumor)
تواريخ الأحداث: Date Created: 20240329 Date Completed: 20240425 Latest Revision: 20240509
رمز التحديث: 20240510
مُعرف محوري في PubMed: PMC11043144
DOI: 10.1007/s10147-024-02493-4
PMID: 38551727
قاعدة البيانات: MEDLINE
الوصف
تدمد:1437-7772
DOI:10.1007/s10147-024-02493-4